ArticleIn vivo (Athens, Greece)
Evaluation of Vascular Proliferation in Molecular Subtypes of Breast Cancer.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 26 citations in OpenAlex.
- Differentiation of Benign and Malignant BI-RADS 4-5 Breast Lesions Using Ultrasound Localization Microscopy-Derived Microvascular Biomarkers: A Prospective Study.Breast cancer (Dove Medical Press) · 2026Article
- Clinical and prognostic effects of microvascular density and FOXP3 positive T cells in breast cancer.Scientific reports · 2024Article
- Personalized Vascularized Models of Breast Cancer Desmoplasia Reveal Biomechanical Determinants of Drug Delivery to the Tumor.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Article
- Prognostic Significance of Microvessel Density in Invasive Ductal Carcinoma of Breast.International journal of hematology-oncology and stem cell research · 2023Article
- Association Between Vascular Index MeasuredFrontiers in oncology · 2022Article
- Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment.Biomarker research · 2021Review
- Review
- Dynamic contrast-enhanced breast MRI features correlate with invasive breast cancer angiogenesis.NPJ breast cancer · 2021Article
- Vascularity and Dynamic Contrast-Enhanced Breast Magnetic Resonance Imaging.Frontiers in radiology · 2021Review
- Engineering Breast Cancer On-chip-Moving Toward Subtype Specific Models.Frontiers in bioengineering and biotechnology · 2021Review
- Diagnostic efficacy of contrast-enhanced ultrasound for breast lesions of different sizes: a comparative study with magnetic resonance imaging.The British journal of radiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAngiogenesis plays a pivotal role in tumor development. Although microvessel density (MVD) is the most common method used for evaluation of angiogenesis, it has several limitations. Our aim was to evaluate MVD and microvessel proliferation (MVP) in a series of invasive breast carcinomas and analyze whether angiogenesis is influenced by the molecular phenotype of each tumor. MATERIALS AND
methodsWe examined vascular proliferation using double immunohistochemistry (CD34/Ki67) in a series of 54 invasive breast carcinomas and compared the results with standard MVD, molecular subtypes and other classical parameters.
resultsIncreased MVD and MVP values were recorded in basal-like subtype, but only the MVP value reached significance among this group of patients (p=0.0001). For all cases combined, increased MVP was significantly correlated with negative estrogen receptor (ER) status (p=0.010) and higher histological grade (p=0.002).
conclusionMVP more accurately reflects the state of angiogenesis in breast cancer, compared with standard MVD. Vascular proliferation was associated with aggressive tumor features, indicating its contribution to tumor progression. The strong association between vascular proliferation and basal-like tumors suggests that this marker can be used for stratification of patients who might benefit from therapies targeting angiogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.